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tion carcinoma) 1 each from pulmonary metastasis and pleural ﬂuid. 
All showed several chromosomal abnormalities. With the modal 
number varying between 56 - 87 chromosomes. The consistent ﬁnding 
in 9/10 cases was a deletion of 3p while 1 had a translocation involving 
chromosome 3. 
In this study tumors irrespective of being a NSCLC or SCLC showed 
that chromosome 3 was consistently involve hinting that this cytoge-
netic proﬁle could evolve as a new diagnostic tool in difﬁcult clinical 
situations. 
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Background: Down-regulation or loss of human leukocyte antigen 
(HLA) class I has been reported in various malignancies in associa-
tion with poor patient survival. These ﬁndings may reﬂect an escape 
of tumor cells losing intact HLA class I molecules from HLA class 
I-restricted, tumor-associated antigen-speciﬁc cytotoxic T lymphocytes 
in recognition as well as in destruction. However, clinical impact of the 
down-regulation or loss of HLA class I in patients with non-small cell 
lung cancer (NSCLC) is still unknown. In the present study, we inves-
tigated clinical signiﬁcance of alteration in expression of HLA class I 
molecules in surgically resected NSCLC using tissue array analysis.
Method: Formalin-ﬁxed parafﬁn-embedded sections were obtained 
from 105 NSCLC (60 adenocarcinoma, 37 squamous cell carcinoma, 
and 6 large cell carcinoma). HLA class I and β2- microglobulin expres-
sion were analyzed using tissue array analysis. Imuunohistochemical 
study was performed using anti-HLA class I mAb EMR8-5 and anti-
β2- microglobulin mAb BBM1/sc-13565. Correlation between HLA 
class I or β2- microglobulin expression and clinicopathological param-
eter was analyzed statistically. Additionally, survival analysis was also 
performed using Kaplan-Meier’s method.
Result: There was no signiﬁcant correlation between HLA class I 
and clinicopathological parameters. On the other hand, signiﬁcant 
correlations were observed between β2- microglobulin expression 
and tumor size(p=0.0003), histological subtype(p=0.0285), nodal 
status(p=0.0335),and pathological stage(p=0.0335). Loss of β2- mi-
croglobulin expression was correlated with poor patient survival 
(p=0.0121), although HLA class I was not(p=0.8243).
Conclusion: Although clinical impact of HLA alteration was still 
unclear, β2- microglobulin expression might be involved in cancer 
progression in human NSCLC possibly through aberration of several 
molecules which contains β2- microglobulin.
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Purpose: To assess the activation patterns of RTK pathways, i.e. pro-
tein kinase B (PKB/Akt) and mitogen activated protein kinase (MAPK) 
pathways, in lung adenocarcinoma as compared with clinico-pathologi-
cal factors and status of EGFR and KRAS mutations. 
Experimental Design: 99 evaluable cases with primary lung adenocar-
cinomas surgically resected between 1998 and 1999 were selected for 
this study. Akt and MAPK phosphorylation (pAkt and pMAPK) was 
examined by means of immunohistochemistry. We deﬁned that cases 
with pAkt+/pMAPK- immunoreactivity to be the “Akt pathway type” 
and the pAkt-/pMAPK+ pattern to be the “MAPK pathway type.” Both 
positive and negative controls were prepared using mouse xenografts 
of PC-3 (pAkt+/MAPK-) and HTB26 (pAkt-/pMAPK+) cell lines. 
Univariate and multivariate analysis were performed to evaluate the 
association of these downstream mainly activated pathways and clinical 
signiﬁcance. The mutational status of EGFR and KRAS was deter-
mined by direct sequencing.
Results: Of the 99 cases, rates of the Akt pathway type and the MAPK 
pathway type were 32% (n=32) and 29% (n=29), respectively. Cases 
with immunoreactivity to both of the antibodies were not included 
in either type. Mutation assay revealed EGFR mutations in 55 cases 
(55%), and KRAS mutation in 7 cases (7%). The predictive factors for 
the MAPK pathway type were cumulative smoking and KRAS muta-
tion by univariate analysis. As all the cases with KRAS mutations were 
strongly positive for pMAPK, KRAS mutation status was mostly a 
highly predictive factor for the Akt pathway type.
Conclusions: Association between Ras/MAPK pathways activa-
tion and KRAS mutations was conﬁrmed in tumor specimens of lung 
adenocarcinoma. The MAPK pathway type was statistically associated 
also with cumulataive smoking. 
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Background: The incidence of lung adenocarcinoma in Korea is 
increasing recently. Estrogen and EGFR pathway may be important in 
lung cancer carcinogenesis. This study was conducted to investigate the 
relationship among expression rate of estrogen receptor(ER), ERCC1, 
Kras and EGFR mutation in adenocarcinoma of the lung.
Material and Method: We performed the retrospective review of 
clinical information that diagnosed as adenocarcinoma of lung at Kosin 
University Gospel Hospital, Busan, South Korea from January 1999 to 
September 2005. Patient’s demographics, stage, serum tumor markers, 
pathologic classiﬁcation were analyzed. EGFR mutations in exons: 18, 
19, 20, 21, and K-ras mutation in exon 12, 13 were analyzed by DNA 
sequencing. The prevalence of ERα, ERβ, and ERCC1 were assessed 
by standard immuonohistochemical (IHC) methods using formalin-
ﬁxed, parafﬁn-embeded tumor specimens. 
Results: For all 84 patients with adenocarcinoma (stage IA in 10, IB 
22, IIA 6, IIB 7, IIIA 25, IIIB 7, and IV 7), 43 (51.2%) were male, 41 
(48.8%) female, and mean age was 57 years old. Mutations of EGFR 
mutations and KRAS were present in 25.7%, 9.5% of samples, respec-
tively. In IHC stain, ER expression was 65.5%, ERα expression in 
41.7%, ERβ in 51.2%, and both expressions in 27.4%. The expression 
rate of ERCC1 was 31%. There were correlation between ER expres-
sion and ERCC1 expression especially in ERβ expression (p=0.000). 
However there was no correlation between ER expression and EFGR 
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mutation. There was no gender difference in ER expression. The 
survival time for patients with the ER mutation was longer (median 
survival time 44.5 months versus 23.5 months), however these differ-
ences were not statistically signiﬁcant. 
Conclusions: There were strong correlation between ERβ and ERCC1 
expression. These expressions may play a role simultaneously in the 
development of adenocarcinoma of the lung.
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Introduction: Epigenetic alterations in certain genes are now known 
as at least important as genetic mutation in pathogenesis of cancer. 
Especially abnormal promotor region methylation in tumor suppressor 
genes is known to result in gene silencing and therefore loss of gene 
function. Objective We, the authors, wanted to search for new lung 
cancer-speciﬁc tumor suppressor genes through the study, and to ﬁgure 
out the roll of known tumor suppressor genes of other kinds of cancer 
for NSCLC as well. 
Material and Methods: Cancer tissue & adjacent normal tissue were 
obtained from 10 patients who diagnosed with NSCLC and underwent 
surgery in Konyang university hospital in 2005. NotI-MseI Methyla-
tion chip was used to analyze DNA methylation on promoter region of 
27 genes in tumor tissue & nearby normally-appearing tissue. The rate 
of methylation was measured and compared for both groups to ﬁnd 
out the genes associated with tomorigenesis. Also the patients were 
grouped by age, gender, history of smoking, and cell type of NSCLC, 
and compared between groups. And as normal control group we ob-
tained lung tissue from two young patients with pneumothorax during 
their bullectomies, methylations were examinated in the same way and 
compared with tumor and non-tumor tissue from NSCLC patients. 
Result: Among the 27 genes, the higher rate of methylation for tumor 
tissue than that of non-tumor tissue were observed in 14 genes, and 6 
genes including AR, HTR1B, CFTR from those 14 genes in normal 
lung tissue were not methylated, suggesting the possibility of the role 
for TSG(tumor suppressor gene) of NSCLC.
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Background: KILLER/DR5 is a recently identiﬁed p53-regulated 
death recpetor gene that was induced by doxorubicine only in cells with 
wild-type p53 status. KILLER gene was also independently identiﬁed 
as a TRAIL (TNF-related Apoptosis-inducing Ligand) death receptor, 
DR5. KILLER/DR5 is now considered as one of the p53-dependent 
apoptotic genes such as fas, bax, or insulin-like growth factor-binding 
protein 3. However, examination of KILLER/DR5 in primary tumour 
tissue has not yet been reported. In this study, we demonstrate that 
KILLER/DR5 expression is dependent on wild-type p53 status in non-
small cell lung cancer (NSCLC). 
Methods and Materials: Immunohistochemical analysis using the 
avidin-biotinylated horseradish peroxidase complex was carried out in 
eighty-nine surgically resected NSCLC formalin-ﬁxed parafﬁn-embed-
ded tissue sections. As primary antibodies, we used anti-DR5 poly-
clonal antibody (Pro Sci Inc., Poway, CA) and anti-p53 monoclonal 
antibody (DO-7, Novocastra, Inc, Manhasset, NY). A negative control 
was processed with each slide; it excluded the primary antibody but in-
cluded all other steps of the procedure. Positive tumor cells were quan-
tiﬁed twice, expressed as a percentage of the total number of tumor 
cells, and the intensity of immunostaining: 1+, weak and diffuse(>50%) 
or focal (<50%) or moderate and focal; 2+, strong and focal or moder-
ate and diffuse; 3+, strong and diffuse. The analysis of DR5 expression 
was done separately in tumor area and regional normal area. 
Results: DR5 expression was high ( > 2+) in bronchial epithelium 
(89% of cases) but almost absent in type I & II pneumocytes, lympho-
cytes, and smooth muscle cells. High DR5 expression rate in tumor was 
28% (15/53) in squamous cell carcinoma, 47%(15/32) in adenocarci-
noma, and 50% (2/4) in large cell carcinoma, overall 36%. DR5 expres-
sion did not show any statistical signiﬁcance with T stage, N stage, 
and survival. However, DR5 expressiont showed signiﬁcant inverse 
correlation with p53 expression. (p < 0.01). If p53 expression was high, 
there was no expression in DR5 and vice versa. 
Conclusions: This signiﬁcant in vivo correlation between p53 expres-
sion and KILLER/DR5 expression is highly suggestive for the fact that 
KILLER/DR5 is one of important p53-dependent apoptotic genes.
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Background: The non-smoking East Asian female with lung adenocar-
cinoma is a phenotype that has been correlated with higher frequencies 
of EGFR mutations, with corresponding increased tumor response to 
tyrosine kinase inhibitors. We hypothesize that estrogen receptor (ER) 
has a role in the biological mechanism underlying this clinical entity, in 
a combinatorial fashion with other signaling transduction components. 
Here, we examine the protein expression levels via immunohistochem-
istry of isoforms of ER, namely ERα and ERβ, progesterone receptor 
(PR), EGFR and HER2.
Methods: Tissue microarrays (TMA): These were constructed from 
parafﬁn-embedded blocks of surgically resected tissues. Each array was 
targeted to contain replicates of 33 adenocarcinomas and 16 squamous 
cell carcinomas, of which 26 and 2 had matched normal lung tissues, 
respectively. 
Immunohistochemistry: Commercially available antibodies identify-
ing ERα, ERβ, PR, EGFR and HER2 were used for staining and detec-
tion, according to the manufacturers’ protocols. The ER, PR and HER2 
analyses used breast invasive ductal carcinomas as positive controls. 
Extent (% of cells) and intensity of staining were scored on a scale of 
